Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma (Q79177549)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

main subject

phase I clinical trial

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

22 March 2024

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

22 March 2024

4

Donald L Morton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Steven O'Day

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Reiko F. Irie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564483

22 March 2024

David W. Ollila

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564483

22 March 2024

Donald L. Morton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564483

22 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14564483

22 March 2024

publication date

16 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

20 December 2019

https://link.springer.com/content/pdf/10.1007/s00262-003-0436-1.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

https://link.springer.com/article/10.1007/s00262-003-0436-1/fulltext.html

22 March 2024

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

http://link.springer.com/content/pdf/10.1007/s00262-003-0436-1

22 March 2024

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Cancer Immunology, Immunotherapy

22 March 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

110-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14564483%20AND%20SRC:MED&resulttype=core&format=json

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

20 December 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

22 March 2024

2

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer

22 March 2024

3

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines

22 March 2024

5

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

22 March 2024

6

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Human monoclonal antibody to ganglioside GM2 for melanoma treatment

22 March 2024

8

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Journal of the National Cancer Institute

22 March 2024

9

66

249

Jones

1981

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

22 March 2024

10

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

The control of homologous lysis

22 March 2024

11

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

22 March 2024

12

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Journal of the National Cancer Institute

22 March 2024

13

87

658

McNeil

1995

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

22 March 2024

14

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

22 March 2024

17

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Murine monoclonal anti-idiotype antibody (alpha) as a probe to detect human monoclonal antibody bound to human tumor tissues

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

22 March 2024

19

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Ganglioside GM2 as a human tumor antigen (OFA-I-1)

22 March 2024

20

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Gangliosides of human melanoma

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

IgM natural antibody against an asialo-oligosaccharide, gangliotetraose (Gg4), sensitizes HIV-I infected cells for cytolysis by homologous complement

22 March 2024

24

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1

Anti-Idiotype Monoclonal Antibody Carrying the Internal Image of Ganglioside GM3

22 March 2024

26

1 reference

https://api.crossref.org/works/10.1007/S00262-003-0436-1